文献速递心脑血管急症重症综合管理与镇静镇痛

墨西哥难治性癫痫持续状态的临床特征与管理挑战:102例回顾性队列研究

Management Challenges and Clinical Characteristics of Refractory Status Epilepticus in Mexico: A 102 Patient Retrospective Cohort Study.
PubMed 文献 · Neurocrit Care · 2026-08-07
一句话结论墨西哥单中心102例RSE回顾性队列:82.4%需三线治疗,87.3%发作终止,住院中位21.5天、机械通气平均8天。

该研究为墨西哥一家三级神经ICU的回顾性队列,纳入2010–2022年≥18岁符合ILAE定义的RSE成人102例(女性52.9%,中位年龄34岁)。病因以感染(23.5%)、结构/血管性(22.5%)和治疗相关(16.7%)为主;82.4%需三线治疗,87.3%发作终止。既往癫痫与既往SE史、发作终止、不良mRS及更高STESS/END-IT评分相关;END-IT还与三线治疗相关。结果提示资源有限环境下RSE管理复杂、护理需求高,但常可获得较好结局。

要点

  • 102例成人RSE中82.4%需三线治疗,87.3%实现发作终止。
  • 中位住院21.5天,机械通气平均8天,提示ICU资源占用高。
  • 病因以感染23.5%、结构/血管性22.5%、治疗相关16.7%为主。
  • 既往癫痫者与既往SE史(p=0.011)、发作终止(p=0.001)、不良mRS(p=0.046)及更高STESS(p=0.001)/END-IT(p=0.021)相关。
  • END-IT评分与需三线治疗相关(p<0.001)。

适用人群与场景

  • 墨西哥一家三级神经ICU的成人(≥18岁)RSE患者,2010–2022年入院,符合ILAE定义。
  • 预设次要分析按既往癫痫分层并识别新发RSE(NORSE),NORSE占29.4%。

诊断标准与关键阈值

  • 采用国际抗癫痫联盟(ILAE)的RSE定义识别患者。
  • 预后评分采用STESS和END-IT。

处置流程与药物剂量

  • 治疗异质性大,82.4%患者需三线治疗;原文未提及具体药物、剂量、途径和疗程。
  • 1例患者接受手术,无并发症。
  • 机械通气平均8天,中位住院21.5天。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 回顾性队列,单中心,102例成人RSE;女性52.9%,中位年龄34(26–44)岁;既往癫痫70.6%,NORSE 29.4%。
  • 病因:感染23.5%、结构/血管性22.5%、治疗相关16.7%;EEG最常见为慢波,发作间期癫痫样放电27.7%。
  • 结局:发作终止87.3%;中位住院21.5天,机械通气平均8天;1例手术无并发症。
  • 既往癫痫与既往SE史(p=0.011)、发作终止(p=0.001)、不良mRS(p=0.046)、更高STESS(p=0.001)和END-IT(p=0.021)相关;END-IT与三线治疗相关(p<0.001)。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:回顾性设计、单中心、样本量102例、治疗异质性大;原文未给出证据等级或推荐强度。

对床旁实践的改变

  • 在资源有限环境下,RSE常需三线治疗且ICU资源占用高(中位住院21.5天、机械通气平均8天),应提前规划床位与通气支持。
  • 既往癫痫患者更常见既往SE史、更高STESS/END-IT评分和不良mRS,提示需更积极评估与分层管理。
  • END-IT评分较高与需三线治疗相关,可作为治疗强度预期的参考,但原文未将其作为决策阈值。
  • 感染、结构/血管性和治疗相关病因占比较高,提示应重视可预防病因的排查。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

There is limited real-world evidence on the diagnosis, treatment, and outcomes of refractory status epilepticus (RSE) in Latin America. This study describes the clinical characteristics, management, and outcomes of RSE in a tertiary neurological intensive care unit (NICU) in Mexico. We conducted a retrospective cohort study of adults (≥ 18 years) with RSE admitted from 2010 to 2022. All patients were initially analyzed as a single cohort; a prespecified secondary analysis stratified patients by preexisting epilepsy and identified those with new-onset RSE (NORSE). Patients were identified via electronic medical records and met the International League Against Epilepsy (ILAE) definition. Clinical, imaging, laboratory, and EEG data were collected. Outcomes included seizure cessation, functional status at NICU discharge (mRS), and prognostic scores (STESS and END-IT). Statistical analysis involved descriptive measures, chi-square/Fisher's exact tests, t-test or Mann-Whitney U test, and multinomial logistic regression. Significance was set at p < 0.05. We analyzed 102 patients with RSE; 52.9% were women, median age 34 (26-44) years. Preexisting epilepsy was present in 70.6%, and 29.4% had NORSE. Most common etiologies were infections (23.5%), structural/vascular (22.5%), and treatment-related (16.7%). EEG most commonly showed slowing; interictal epileptiform discharges appeared in 27.7%. Treatment was heterogeneous; 82.4% required third-line therapy. Median hospitalization was 21.5 days, with mechanical ventilation averaging 8 days. Resolution occurred in 87.3%. One patient underwent surgery, without complications. Preexisting epilepsy was significantly associated with prior SE (p = 0.011), resolution (p = 0.001), unfavorable mRS (p = 0.046), and higher STESS (p = 0.001) and END-IT (p = 0.021) scores. END-IT also correlated with third-line treatment (p < 0.001). This study offers real-world insights into RSE in a resource-limited setting, highlighting preventable causes, management complexity, and high care demands. Despite limitations, favorable outcomes are often achievable.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Cruz-Perez J, Zepeda-Pérez JA, Camacho-Castillo EZ, et al. Management Challenges and Clinical Characteristics of Refractory Status Epilepticus in Mexico: A 102 Patient Retrospective Cohort Study. Neurocrit Care. 2026. PMID: 42568019. doi:10.1007/s12028-026-02597-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。